translational-oncology
(2)
Sus Clinicals, Inc.
Sus Clinicals, Inc. is a Cincinnati- and Chicago-based biotechnology company commercializing the Oncopig Cancer Model - a genetically engineered pig that develops human-like tumors on demand. Billed as the only FDA-cleared large animal cancer platform, the Oncopig carries KRAS and TP53 mutations found in more than half of human cancers, giving drug, device, and diagnostic developers a predictive testing ground that sits between the mouse and the human clinical trial. Alongside live animal supply, the company runs histology services and a tumor-tissue biorepository, and partners with CROs across the US and Europe.
Jessicca Rege
Jessicca M. Rege, Ph.D. is the Chief Executive Officer of Sus Clinicals, Inc., a biotech accelerating cancer drug development through the Oncopig Cancer Model, an FDA-cleared, genetically engineered pig platform for preclinical testing. A pharmaceutical scientist with more than 15 years in oncology R&D and global medical affairs, she previously served as Chief Development Officer at Mural Oncology, where she helped lead the company's public offering, and as VP, Head of Clinical Development, Oncology at Alkermes. She holds a Ph.D. in pharmaceutical sciences with a focus on pharmacogenomics from Virginia Commonwealth University.